CRADLE-5: a stepped-wedge type 2 hybrid implementation-effectiveness cluster randomised controlled trial to evaluate the real-world scale-up of the CRADLE Vital Signs Alert intervention into routine maternity care in Sierra Leone-study protocol.
Blood pressure
CRADLE
Complex intervention
Low- and middle-income countries
Maternal mortality
Pre-eclampsia
Scale-up
Shock
Sierra Leone
Stepped-wedge cluster trial
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
15 Sep 2023
15 Sep 2023
Historique:
received:
20
06
2023
accepted:
16
08
2023
medline:
20
9
2023
pubmed:
19
9
2023
entrez:
18
9
2023
Statut:
epublish
Résumé
The CRADLE Vital Signs Alert intervention (an accurate easy-to-use device that measures blood pressure and pulse with inbuilt traffic-light early warning system, and focused training package) was associated with reduced rates of eclampsia and maternal death when trialled in urban areas in Sierra Leone. Subsequently, implementation was successfully piloted as evidenced by measures of fidelity, feasibility and adoption. The CRADLE-5 trial will examine whether national scale-up, including in the most rural areas, will reduce a composite outcome of maternal and fetal mortality and maternal morbidity and will evaluate how the CRADLE package can be embedded sustainably into routine clinical pathways. CRADLE-5 is a stepped-wedge cluster-randomised controlled trial of the CRADLE intervention compared to routine maternity care across eight rural districts in Sierra Leone (Bonthe, Falaba, Karene, Kailahun, Koinadugu, Kono, Moyamba, Tonkolili). Each district will cross from control to intervention at six-weekly intervals over the course of 1 year (May 2022 to June 2023). All women identified as pregnant or within six-weeks postpartum presenting for maternity care in the district are included. Primary outcome data (composite rate of maternal death, stillbirth, eclampsia and emergency hysterectomy) will be collected. A mixed-methods process and scale-up evaluation (informed by Medical Research Council guidance for complex interventions and the World Health Organization ExpandNet tools) will explore implementation outcomes of fidelity, adoption, adaptation and scale-up outcomes of reach, maintenance, sustainability and integration. Mechanisms of change and contextual factors (barriers and facilitators) will be assessed. A concurrent cost-effectiveness analysis will be undertaken. International guidance recommends that all pregnant and postpartum women have regular blood pressure assessment, and healthcare staff are adequately trained to respond to abnormalities. Clinical effectiveness to improve maternal and perinatal health in more rural areas, and ease of integration and sustainability of the CRADLE intervention at scale has yet to be investigated. This trial will explore whether national scale-up of the CRADLE intervention reduces maternal and fetal mortality and severe maternal adverse outcomes and understand the strategies for adoption, integration and sustainability in low-resource settings. If successful, the aim is to develop an adaptable, evidence-based scale-up roadmap to improve maternal and infant outcomes. ISRCTN 94429427. Registered on 20 April 2022.
Sections du résumé
BACKGROUND
BACKGROUND
The CRADLE Vital Signs Alert intervention (an accurate easy-to-use device that measures blood pressure and pulse with inbuilt traffic-light early warning system, and focused training package) was associated with reduced rates of eclampsia and maternal death when trialled in urban areas in Sierra Leone. Subsequently, implementation was successfully piloted as evidenced by measures of fidelity, feasibility and adoption. The CRADLE-5 trial will examine whether national scale-up, including in the most rural areas, will reduce a composite outcome of maternal and fetal mortality and maternal morbidity and will evaluate how the CRADLE package can be embedded sustainably into routine clinical pathways.
METHODS
METHODS
CRADLE-5 is a stepped-wedge cluster-randomised controlled trial of the CRADLE intervention compared to routine maternity care across eight rural districts in Sierra Leone (Bonthe, Falaba, Karene, Kailahun, Koinadugu, Kono, Moyamba, Tonkolili). Each district will cross from control to intervention at six-weekly intervals over the course of 1 year (May 2022 to June 2023). All women identified as pregnant or within six-weeks postpartum presenting for maternity care in the district are included. Primary outcome data (composite rate of maternal death, stillbirth, eclampsia and emergency hysterectomy) will be collected. A mixed-methods process and scale-up evaluation (informed by Medical Research Council guidance for complex interventions and the World Health Organization ExpandNet tools) will explore implementation outcomes of fidelity, adoption, adaptation and scale-up outcomes of reach, maintenance, sustainability and integration. Mechanisms of change and contextual factors (barriers and facilitators) will be assessed. A concurrent cost-effectiveness analysis will be undertaken.
DISCUSSION
CONCLUSIONS
International guidance recommends that all pregnant and postpartum women have regular blood pressure assessment, and healthcare staff are adequately trained to respond to abnormalities. Clinical effectiveness to improve maternal and perinatal health in more rural areas, and ease of integration and sustainability of the CRADLE intervention at scale has yet to be investigated. This trial will explore whether national scale-up of the CRADLE intervention reduces maternal and fetal mortality and severe maternal adverse outcomes and understand the strategies for adoption, integration and sustainability in low-resource settings. If successful, the aim is to develop an adaptable, evidence-based scale-up roadmap to improve maternal and infant outcomes.
TRIAL REGISTRATION
BACKGROUND
ISRCTN 94429427. Registered on 20 April 2022.
Identifiants
pubmed: 37723530
doi: 10.1186/s13063-023-07587-4
pii: 10.1186/s13063-023-07587-4
pmc: PMC10506317
doi:
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
590Subventions
Organisme : NIHR
ID : NIHR133232
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Implement Sci. 2019 Apr 18;14(1):38
pubmed: 30999963
Stat Methods Med Res. 2021 Feb;30(2):425-439
pubmed: 32970526
BMJ Innov. 2018 Oct;4(4):192-198
pubmed: 30319784
Blood Press Monit. 2015 Feb;20(1):52-5
pubmed: 25243711
Health Res Policy Syst. 2017 Jul 12;15(Suppl 1):49
pubmed: 28722561
Lancet Glob Health. 2019 Mar;7(3):e347-e356
pubmed: 30784635
Contemp Clin Trials. 2007 Feb;28(2):182-91
pubmed: 16829207
BMJ. 2014 Mar 07;348:g1687
pubmed: 24609605
Global Health. 2019 Jan 22;15(1):8
pubmed: 30670026
Blood Press Monit. 2008 Dec;13(6):342-8
pubmed: 19020425
Reprod Health. 2023 Jan 6;20(1):6
pubmed: 36609353
Adm Policy Ment Health. 2011 Mar;38(2):65-76
pubmed: 20957426
BMJ. 2020 Nov 25;371:m4075
pubmed: 33239272
Sex Reprod Health Matters. 2020 Dec;28(1):1818376
pubmed: 33073741
BMJ. 2018 Nov 9;363:k1614
pubmed: 30413417
Trials. 2018 Mar 27;19(1):206
pubmed: 29587875
BJOG. 2015 Jan;122(2):268-75
pubmed: 25546050
Med Care. 2012 Mar;50(3):217-26
pubmed: 22310560
Stat Med. 2018 Jul 20;37(16):2487-2500
pubmed: 29635789
BMJ. 2021 Sep 30;374:n2061
pubmed: 34593508
PLoS One. 2016 Dec 20;11(12):e0168535
pubmed: 27997586
Pregnancy Hypertens. 2018 Apr;12:183-188
pubmed: 29175171
Blood Press Monit. 2015 Oct;20(5):299-302
pubmed: 26020367